Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605520836 | ||
| 003 | CHVBK | ||
| 005 | 20210128100737.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-015-0037-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-015-0037-y | ||
| 245 | 0 | 0 | |a Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs |h [Elektronische Daten] |c [Johanna Driessen, Hein van Onzenoort, Jakob Starup-Linde, Ronald Henry, Andrea Burden, Cees Neef, Joop van den Bergh, Peter Vestergaard, Frank de Vries] |
| 520 | 3 | |a Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs that might have a potential beneficial effect on bone metabolism. Data on the effect of GLP-1 RAs and fracture risk are lacking. The aim of the present study was to investigate the association between the use of GLP-1 and the risk of fracture. A case-control study was performed using Danish National Health Service data. Cases were those who sustained a fracture and controls were those without a fracture during the study period (2007-2011), all aged 18years and above. Conditional logistic regression estimated the odds ratios (OR) of fracture with current use of DPP4-I use. Analyses were adjusted for comorbidities and recent drug use. Among cases (n=229,114), there were 6993 current non-insulin anti-diabetic drug (NIAD) users (excluding incretin users) and 255 GLP-1 RA users. Similarly, among controls (n=229,114), 7209 were NIAD users (excluding incretin users) and 220 were GLP-1 RA users. Current GLP-1 RA use was not associated with a decreased risk of fracture [adjusted (adj.) OR 1.16; 95% CI 0.83-1.63]. Osteoporotic fracture risk was also not associated with current GLP-1 RA use (adj. OR 0.78; 95% CI 0.44-1.39). In our nation-wide case-control study, we identified that the use of GLP-1 RA was not associated with fracture risk as compared to the use of other anti-hyperglycemic drugs. Additionally, current GLP-1 RA use, stratified by cumulative or average daily dose, is not associated with fracture risk. Further research should focus on long-term use of GLP-1 RA and fracture risk. | |
| 540 | |a The Author(s), 2015 | ||
| 690 | 7 | |a GLP-1 RA |2 nationallicence | |
| 690 | 7 | |a Fracture |2 nationallicence | |
| 690 | 7 | |a Type 2 diabetes mellitus |2 nationallicence | |
| 690 | 7 | |a Case-control |2 nationallicence | |
| 700 | 1 | |a Driessen |D Johanna |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a van Onzenoort |D Hein |u Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | |
| 700 | 1 | |a Starup-Linde |D Jakob |u Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |4 aut | |
| 700 | 1 | |a Henry |D Ronald |u Department of Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | |
| 700 | 1 | |a Burden |D Andrea |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a Neef |D Cees |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a van den Bergh |D Joop |u Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | |
| 700 | 1 | |a Vestergaard |D Peter |u Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |4 aut | |
| 700 | 1 | |a de Vries |D Frank |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/5(2015-11-01), 506-515 |x 0171-967X |q 97:5<506 |1 2015 |2 97 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-015-0037-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-015-0037-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Driessen |D Johanna |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a van Onzenoort |D Hein |u Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Starup-Linde |D Jakob |u Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Henry |D Ronald |u Department of Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Burden |D Andrea |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Neef |D Cees |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a van den Bergh |D Joop |u Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Vestergaard |D Peter |u Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a de Vries |D Frank |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/5(2015-11-01), 506-515 |x 0171-967X |q 97:5<506 |1 2015 |2 97 |o 223 | ||